Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation

Transplantation

Volumn 93, Issue 10, 2012, Pages 1024-1030

  Oshita, Akihiko ^a   Tashiro, Hirotaka ^a   Amano, Hironobu ^a   Kobayashi, Tsuyoshi ^a   Onoe, Takashi ^a   Ide, Kentaro ^a   Takaki, Shintaro ^a   Takahashi, Shoichi ^a   Arihiro, Koji ^b   Chayama, Kazuaki ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biopsy; Diet; Fatty liver; Living donor liver transplantation; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT OBSTRUCTION; BILE LEAKAGE; BODY MASS; BUDD CHIARI SYNDROME; CONSULTATION; CONTROLLED STUDY; DIET; DISEASE SEVERITY; EXERCISE; FATTY LIVER; FEASIBILITY STUDY; FEMALE; FULMINANT HEPATIC FAILURE; HUMAN; HUMAN TISSUE; INSULINOMA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER REGENERATION; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE COMPLICATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SAFETY; WILSON DISEASE;

ADULT; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; REFERRAL AND CONSULTATION;

EID: 84861099245     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824c9e25     Document Type: Article

References (37)

1. Botha JF, Thompson E, Gilroy R, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007; 27: 758.
2. Todo S, Demetris AJ, Makowka L, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989; 47: 903.
3. D'Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991; 51: 157.
4. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantationVA multivariate analysis. Transplantation 1993; 55: 807.
5. Marsman WA, Wiesner RH, Rodriguez L, et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246.
6. Imber CJ, St Peter SD, Handa A, et al. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002; 8: 415.
7. Fan ST. Live donor liver transplantation in adults. Transplantation 2006; 82: 723.
8. Strong RW, Lynch SV, Ong TH, et al. Successful liver transplantation from a living donor to her son. N Engl J Med 1990; 322: 1505.
9. Soejima Y, Shimada M, Suehiro T, et al. Use of steatotic graft in livingdonor liver transplantation. Transplantation 2003; 76: 344.
10. Nakamuta M, Morizono S, Soejima Y, et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005; 80: 608.
11. Miller CM. Ethical dimensions of living donation: Experience with living liver donation. Transplant Rev (Orlando) 2008; 22: 206.
12. Hwang S, Lee SG, Lee YJ, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: How to make living donations safe. Liver Transpl 2006; 12: 920.
13. Hayashi M, Fujii K, Kiuchi T, et al. Effects of fatty infiltration of the graft on the outcome of living-related liver transplantation. Transplant Proc 1999; 31: 403.
14. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205.
15. Fan ST, Lo CM, Liu CL, et al. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg 2000; 135: 336.
16. Middleton PF, Duffield M, Lynch SV, et al. Living donor liver transplantationVAdult donor outcomes: A systematic review. Liver Transpl 2006; 12: 24.
17. Seifalian AM, Chidambaram V, Rolles K, et al. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transpl Surg 1998; 4: 71.
18. Fukumori T, Ohkohchi N, Tsukamoto S, et al. The mechanism of injury in a steatotic liver graft during cold preservation. Transplantation 1999; 67: 195.
19. Oliva MR, Mortele KJ, Segatto E, et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 2006; 30: 37.
20. Oza N, Eguchi Y, Mizuta T, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009; 44: 1203.
21. Karcaaltincaba M, Akhan O. Imaging of hepatic steatosis and fatty sparing. Eur J Radiol 2007; 61: 33.
22. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71.
23. Rinella ME, Alonso E, Rao S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001; 7: 409.
24. Peng CJ, Yuan D, Li B, et al. Body mass index evaluating donor hepatic steatosis in living donor liver transplantation. Transplant Proc 2009; 41: 3556.
25. Nadalin S, Malago M, Valentin-Gamazo C, et al. Preoperative donor liver biopsy for adult living donor liver transplantation: Risks and benefits. Liver Transpl 2005; 11: 980.
26. Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2: 292.
27. Cho JY, Suh KS, Kwon CH, et al. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. Surgery 2006; 139: 508.
28. Yokoi H, Isaji S, Yamagiwa K, et al. Donor outcome and liver regeneration after right-lobe graft donation. Transpl Int 2005; 18: 915.
29. Selzner M, Clavien PA. Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway. Hepatology 2000; 31: 35.
30. Nagai S, Fujimoto Y, Kamei H, et al. Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy. Br J Surg 2009; 96: 437.
31. Baccarani U, Isola M, Adani GL, et al. Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications. Clin Transplant 2010; 24: 631.
32. Mustajoki P, Pekkarinen T. Very low energy diets in the treatment of obesity. Obes Rev 2001; 2: 61.
33. Miyawaki T, Masuzaki H, Ogawa Y, et al. Clinical implications of leptin and its potential humoral regulators in long-term low-calorie diet therapy for obese humans. Eur J Clin Nutr 2002; 56: 593.
34. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467.
35. Itamoto T, Emoto K, Mitsuta H, et al. Safety of donor right hepatectomy for adult-to-adult living donor liver transplantation. Transpl Int 2006; 19: 177.
36. Tashiro H, Itamoto T, Sasaki T, et al. Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: Causes and treatment. World J Surg 2007; 31: 2222.
37. Tanaka Y, Ohdan H, Onoe T, et al. Low incidence of acute rejection after living-donor liver transplantation: Immunologic analyses by mixed lymphocyte reaction using a carboxyfluorescein diacetate succinimidyl ester labeling technique. Transplantation 2005; 79: 1262.